Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longxiang Pingchuan capsule for chronic persistent bronchial asthma
ChiCTR2200066722Phase 4Not yet recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Nov 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Longxiang Pingchuan in asthma (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Good asthma control rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Longxiang Pingchuan
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2200066722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066722.